Characteristics of patients of the derivation series at the initiation of the first 3 lines of treatment
| Characteristic . | First (n = 121) . | Second (n = 66) . | Third (n = 39) . |
|---|---|---|---|
| Age, median (IQR), y | 70 (61-80) | 70.8 (63.4-78.4) | 69.6 (61.9-76.0) |
| ≤65 | 46 (38) | 19 (32) | 12 (31) |
| >65 | 75 (62) | 47 (68) | 27 (69) |
| Hemoglobin, median (IQR), g/dL | 9.4 (8.5-11.0) | 9.5 (8.4-11.2) | 9.8 (8.4-11.0) |
| <10 | 72 (64) | 37 (61) | 16 (52) |
| 10-11.5 | 17 (15) | 9 (15) | 10 (32) |
| >11.5 | 24 (21) | 15 (24) | 5 (16) |
| Missing | 8 | 5 | 8 |
| Platelet count, median (IQR), ×109/L | 230 (159-324) | 200 (125-287) | 176 (106-300) |
| ≤100 | 19 (17) | 13 (22) | 7 (23) |
| >100 | 94 (83) | 46 (78) | 24 (77) |
| Missing | 8 | 7 | 8 |
| Serum β2-microglobulin, median (IQR), mg/L | 3.2 (2.4-4.8) | 2.9 (2.3-5.5) | 3.18 (2.23-6.6) |
| ≤3 | 45 (43) | 21 (52.5) | 8 (42) |
| >3 | 59 (57) | 19 (47.5) | 11 (58) |
| Missing | 17 | 26 | 20 |
| Serum mIgM, median (IQR), g/L | 23 (14-35.7) | 24 (12.7-38.6) | 23.4 (12.3-34) |
| Missing | 6 | 2 | 2 |
| IPSSWM | |||
| Low or intermediate | 62 (60) | 32 (63) | 16 (59) |
| High | 42 (40) | 19 (37) | 11 (41) |
| Missing | 17 | 15 | 12 |
| Response* | |||
| CR, VGPR, and PR | 47† (41) | 25 (41) | 15 (47) |
| MR | 33 (30) | 12 (20) | 4 (13) |
| Stable | 23 (20) | 18 (29) | 9 (28) |
| Progression | 2 (2) | 3 (5) | 1 (3) |
| Death | 8 (7) | 3 (5) | 3 (9) |
| NA | 8 | 5 | 7 |
| Characteristic . | First (n = 121) . | Second (n = 66) . | Third (n = 39) . |
|---|---|---|---|
| Age, median (IQR), y | 70 (61-80) | 70.8 (63.4-78.4) | 69.6 (61.9-76.0) |
| ≤65 | 46 (38) | 19 (32) | 12 (31) |
| >65 | 75 (62) | 47 (68) | 27 (69) |
| Hemoglobin, median (IQR), g/dL | 9.4 (8.5-11.0) | 9.5 (8.4-11.2) | 9.8 (8.4-11.0) |
| <10 | 72 (64) | 37 (61) | 16 (52) |
| 10-11.5 | 17 (15) | 9 (15) | 10 (32) |
| >11.5 | 24 (21) | 15 (24) | 5 (16) |
| Missing | 8 | 5 | 8 |
| Platelet count, median (IQR), ×109/L | 230 (159-324) | 200 (125-287) | 176 (106-300) |
| ≤100 | 19 (17) | 13 (22) | 7 (23) |
| >100 | 94 (83) | 46 (78) | 24 (77) |
| Missing | 8 | 7 | 8 |
| Serum β2-microglobulin, median (IQR), mg/L | 3.2 (2.4-4.8) | 2.9 (2.3-5.5) | 3.18 (2.23-6.6) |
| ≤3 | 45 (43) | 21 (52.5) | 8 (42) |
| >3 | 59 (57) | 19 (47.5) | 11 (58) |
| Missing | 17 | 26 | 20 |
| Serum mIgM, median (IQR), g/L | 23 (14-35.7) | 24 (12.7-38.6) | 23.4 (12.3-34) |
| Missing | 6 | 2 | 2 |
| IPSSWM | |||
| Low or intermediate | 62 (60) | 32 (63) | 16 (59) |
| High | 42 (40) | 19 (37) | 11 (41) |
| Missing | 17 | 15 | 12 |
| Response* | |||
| CR, VGPR, and PR | 47† (41) | 25 (41) | 15 (47) |
| MR | 33 (30) | 12 (20) | 4 (13) |
| Stable | 23 (20) | 18 (29) | 9 (28) |
| Progression | 2 (2) | 3 (5) | 1 (3) |
| Death | 8 (7) | 3 (5) | 3 (9) |
| NA | 8 | 5 | 7 |
Values are number (percentage) of patients unless otherwise indicated.
IQR, interquartile range; NA, not available.
As reported by physician, according to international recommendations. Please note that categorical response could not be defined as stable before the first 6 months of treatment.
Including 2 CR and 9 VGPR.